These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37520615)

  • 21. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
    van Hage-Hamsten M; Johansson E; Roquet A; Peterson C; Andersson M; Greiff L; Vrtala S; Valenta R; Grönneberg R
    Clin Exp Allergy; 2002 Oct; 32(10):1448-53. PubMed ID: 12372124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study.
    Gevaert P; De Craemer J; De Ruyck N; Rottey S; de Hoon J; Hellings PW; Volckaert B; Lesneuck K; Orengo JM; Atanasio A; Kamal MA; Abdallah H; Kamat V; Dingman R; DeVeaux M; Ramesh D; Perlee L; Wang CQ; Weinreich DM; Herman G; Yancopoulos GD; O'Brien MP
    J Allergy Clin Immunol; 2022 Jan; 149(1):189-199. PubMed ID: 34126156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
    Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeatability of nasal allergen challenge results: Further validation of the allergic rhinitis clinical investigator collaborative protocols.
    Soliman M; Steacy LM; Thiele J; Adams DE; Neighbour HL; Ellis AK
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):607-613. PubMed ID: 29432965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis.
    Karatzas K; Katsifarakis N; Riga M; Werchan B; Werchan M; Berger U; Pfaar O; Bergmann KC
    Allergy; 2018 Sep; 73(9):1851-1859. PubMed ID: 29791010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different Development Forms of Local Allergic Rhinitis towards Birch.
    Bozek A; Winterstein J; Galuszka B; Jarzab J
    Biomed Res Int; 2020; 2020():3408561. PubMed ID: 32596297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Differences between Local and Systemic Allergic Rhinitis Induced by Birch Pollen.
    Bozek A; Zalejska Fiolka J; Krajewska Wojtys A; Galuszka B; Cudak A
    Int Arch Allergy Immunol; 2020; 181(11):831-838. PubMed ID: 32772017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the reproducibility of responses to nasal allergen challenge and effects of inhaled nasal corticosteroids.
    Bauer RN; Xie Y; Beaudin S; Wiltshire L; Wattie J; Muñoz C; Alsaji N; Oliveria JP; Ju X; MacLean J; Sommer DD; Keith PK; Satia I; Cusack RP; O'Byrne PM; Sperinde G; Hokom M; Li O; Banerjee P; Chen C; Staton T; Sehmi R; Gauvreau GM
    Clin Exp Allergy; 2023 Nov; 53(11):1187-1197. PubMed ID: 37794659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo.
    Gilles-Stein S; Beck I; Chaker A; Bas M; McIntyre M; Cifuentes L; Petersen A; Gutermuth J; Schmidt-Weber C; Behrendt H; Traidl-Hoffmann C
    Clin Exp Allergy; 2016 Oct; 46(10):1355-65. PubMed ID: 27061126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens.
    Mittag D; Vieths S; Vogel L; Becker WM; Rihs HP; Helbling A; Wüthrich B; Ballmer-Weber BK
    J Allergy Clin Immunol; 2004 Jan; 113(1):148-54. PubMed ID: 14713921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual wearable air purifier protects against pollen, house dust mite, and cat allergens: Report from an allergen exposure chamber.
    Bergmann KC; Hartung T; Zuberbier T
    Allergol Select; 2024; 8():70-77. PubMed ID: 38549812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nasal cytology can predict clinical efficacy of subcutaneous immunotherapy in intermittent allergic rhinitis.
    Jura-Szołtys E; Gawlik R; Branicka O; Stryjewska-Makuch G; Glück J
    Postepy Dermatol Alergol; 2022 Dec; 39(6):1110-1115. PubMed ID: 36686010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
    Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
    EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy.
    Neighbour H; Soliman M; Steacy LM; Hickey P; Forbes B; Larché M; Ellis AK
    Clin Transl Allergy; 2018; 8():15. PubMed ID: 29682277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of N-acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber.
    de Blay F; Gherasim A; Domis N; Choual I; Bourcier T
    Clin Exp Allergy; 2022 Sep; 52(9):1091-1100. PubMed ID: 35302688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.